StockResearch Intelligence Weekly #19

1. After the Binary: The Week the Market Got Its AI Answer, But Not Its Fed Relief

The S&P 500 closed at 7,473.47 — an eighth consecutive weekly gain — but the leadership underneath it flipped. The Dow (+2.1% on the week) and the Russell 2000 (+2.7%) outran the Nasdaq (+0.5%), the first clean sign in months that the tape no longer needs a narrow mega-cap technology cohort to do all the work. AI still matters. It is simply no longer the only usable playbook.

Three forces drove the week, and they did not align.

First, Nvidia delivered — and then some. Q1 FY27 revenue hit $81.6 billion, up 85% year over year and 20% sequentially, with Data Center alone contributing $75.2 billion (+92% Y/Y). Non-GAAP gross margin held at 74.9%, non-GAAP EPS landed at $1.87, and management guided next-quarter revenue to roughly $91 billion. But the more revealing move was capital allocation: Nvidia raised its quarterly dividend 25-fold and authorized a fresh $80 billion buyback, returning a record $20 billion to shareholders in the quarter. A company still in pure land-grab mode does not do that. The AI infrastructure thesis survived its single biggest binary — and management quietly signaled the hyper-growth phase is beginning to mature into a cash-return phase.

Second, the Fed did not hand the market a permission slip. The April decision produced four dissents — the most since 1992 — and the May 20 minutes showed more policymakers open to a rate hike if inflation stays persistent. That matters because the market had been leaning on a three-part thesis: earnings resilience, AI strength, and eventual policy relief. This week confirmed the first two and explicitly withheld the third.

Third, the inflation backdrop stayed uncomfortable. April CPI rose 3.8% year over year, with core at 2.8%, energy up 17.9%, and food up 3.2%. PPI compounded the picture, rising 1.4% month over month and 6.0% year over year. The market rallied anyway — but it did not rally because the macro improved. It rallied because earnings, AI capex, and breadth were strong enough to absorb the macro damage.

Key themes this week:

• AI demand cleared its most important near-term test — but Nvidia’s pre-event setup is now spent, and the dividend pivot says management knows it.
• Breadth improved, with the Russell 2000 and the Dow leading the Nasdaq.
• The Fed minutes and the inflation data kept the rate-cut trade on a short leash.
• The best setups now demand rotation discipline, not simply owning the best companies at any price.

2. Strengths

• AI infrastructure demand was validated at scale. Nvidia’s print confirmed the AI capex cycle is real, large, and still accelerating. The $81.6 billion revenue result, the $75.2 billion Data Center line, and the $91 billion forward guide reset the demand floor for the entire chain — semiconductors, networking, data-center power, and server supply. The honest read on the stock itself: the catalyst that justified Nvidia as a Top 3 pick has now fired, so it shifts from pre-event asymmetry to post-event digestion. The thesis is intact; the trade has changed shape.
• Breadth improved at exactly the right time. The Russell 2000 rose 2.7% on the week, the Dow gained 2.1%, and the Nasdaq lagged at 0.5%. This does not mean the market has rotated out of AI. It means the tape is no longer hostage to a handful of mega-cap names. The move was visible at the single-stock level too — Dell and HP jumped sharply on AI-server demand expectations into their own prints, Workday climbed on a well-received quarter, and Merck led the Dow on oncology data. Money is fanning out across the AI supply chain, healthcare, and small caps. The one condition: small-cap leadership needs stable yields. If the long end pushes higher again, this breadth can reverse quickly.
• Consumer earnings were better than the macro story implied. Walmart reported 7.3% revenue growth and 26% global e-commerce growth. Target delivered 6.7% net sales growth and 5.6% comparable sales growth. Home Depot was the soft spot — adjusted EPS fell year over year — but sales still rose 4.8% and management reaffirmed full-year guidance. The consumer is clearly pressured by energy and food inflation, but the prints do not describe a consumer that is breaking.

3. Weaknesses

• The Fed risk did not go away. A market can absorb a hawkish Fed when earnings are strong. It cannot ignore one indefinitely. The April meeting’s four dissents and the May 20 minutes’ open discussion of potential hikes mean the policy backdrop is no longer a clean tailwind for risk assets — it is a constraint. That weighs most heavily on the duration-sensitive corners of the market: software, small caps, housing, and real estate.
• Inflation is moving in the wrong direction. CPI at 3.8% and PPI at 6.0% are not the numbers of a confident easing cycle. Energy remains the transmission mechanism, with CPI energy up 17.9% year over year. Oil did cool later in the week as peace-talk headlines improved — a genuine relief — but the April inflation data had already tightened the Fed’s room to maneuver before that happened. The easing runway is narrower than it looked a month ago.
• AI leadership is becoming more expensive and more event-dependent. Nvidia’s numbers were excellent — but excellence was the expected standard, and the stock faded post-print even on a clean beat. That is precisely why the publication rotates this week. Once a thesis-resolving catalyst fires, the bar moves higher and the easy asymmetry is gone. The work now is to find the unfired catalysts downstream: AI infrastructure suppliers with their own prints still ahead, beaten-down software with reset expectations, and non-tech names with real near-term data flow.

4. Weekly Market Recap

The market got the Nvidia confirmation it needed, but not the Fed relief it wanted.

The week’s cross-asset message was cleaner than the daily noise: AI demand held, breadth improved, oil eased from panic levels, and volatility stayed contained. But the Fed minutes and inflation data capped the enthusiasm. This was not a low-rate melt-up. It was an earnings-led, breadth-supported rally with macro risk still alive underneath.

The S&P 500 finished just below the prior high zone, the Dow moved to a fresh record area, and the Russell 2000 outperformed as risk appetite broadened. The Nasdaq lagged on a relative basis because the market has already paid heavily for the most obvious AI winners. That distinction matters. The next leg of the rally likely depends less on Nvidia itself and more on whether the Nvidia read-through lifts the broader AI infrastructure chain, software can stabilize, and small caps can hold their bid despite a hawkish Fed.

5. Top 3 Stock Picks for Long-Term Investment

The Top 3 resets this week.

NVDA, MSFT, and LLY anchored the Top 3 across Editions #16 through #18, and #18 itself framed Nvidia’s May 20 earnings as the decisive binary. That binary has now fired. Microsoft remains a high-quality AI compounder, but it does not have a company-specific, unfired catalyst inside the next six weeks. Eli Lilly remains one of the strongest secular healthcare stories in the market, but its next earnings catalyst sits in August — outside the near-term window.

This is not a downgrade of company quality. It is a discipline call. When asymmetry narrows, rotate.

#1. Broadcom (AVGO): BUY, AI infrastructure re-entry

Price: $414.14 | Market Cap: approximately $2.0T | Forward P/E: approximately 36x to 37x | 52W Range: $231.13 to $442.36 | Earnings: June 3, 2026 AMC

Thesis. Broadcom is the cleaner post-Nvidia re-entry than Nvidia itself. Nvidia validated the AI infrastructure cycle, but its own catalyst has already fired. Broadcom’s has not. The company sits directly inside the next layer of AI capex — custom silicon, networking, connectivity, and infrastructure software — and reports before the market has fully repriced the Nvidia read-through.

Why now. Broadcom reports Q2 FY26 on June 3, giving the stock a near-term, company-specific catalyst. The prior guide was strong: management pointed to roughly $22 billion in Q2 revenue, up about 47% year over year, with adjusted EBITDA near 68% of revenue. If Nvidia’s print confirmed the spending cycle exists, Broadcom’s print tests how far that cycle is broadening into custom silicon and networking — the part of the chain that benefits as hyperscalers diversify their own designs.

Key levels. First support sits near $410, then $400, with the more important risk-management line near $385. Resistance sits near $442, the 52-week-high zone; a weekly close above it shifts the setup from recovery to breakout. Below $385, the event-risk math deteriorates.

Risk factors. Broadcom is not cheap. At roughly 36–37x forward earnings, the stock needs clean AI revenue acceleration and margin conversion to justify the multiple. A softer custom-silicon outlook, slower networking demand, or weaker infrastructure-software contribution would all pressure it. The stock is also exposed to a broader AI unwind if investors decide Nvidia’s print marked peak enthusiasm rather than another leg up.

Verdict: BUY on disciplined entry. Most public consensus ranges cluster in the mid-to-high $400s. My 12-month target band: $455–$480 base case, $520 stretch on another AI estimate-reset cycle. Stop discipline below $385.

#2. Salesforce (CRM): BUY, beaten-down software reset into earnings

Price: $180.07 | Market Cap: approximately $170B, vendor-dependent | Forward P/E: approximately 12x to 13x | 52W Range: $163.52 to approximately $280.74 | Earnings: May 27, 2026 AMC

Thesis. Salesforce is not the cleanest AI story in the market — and that is the opportunity. The stock has already been de-rated, sentiment has moved away from software-AI narratives, and expectations sit materially lower than a year ago. In a week where Nvidia proved AI infrastructure demand is intact, Salesforce becomes the test of whether AI can re-enter the software earnings story. A depressed base is the setup; the print is the trigger.

Why now. Salesforce reports Q1 FY27 on May 27 after the close. The company previously guided Q1 FY27 revenue to roughly $11.03–$11.08 billion, and external estimates sit in the same range. If revenue holds, margins are stable, and management gives credible — not promotional — commentary on AI agent adoption, the stock can re-rate from a low starting point. The expectations bar is the lowest it has been in the publication’s coverage window.

Key levels. First support sits at $175–$180; deeper support near $163–$165, the 52-week-low area. Resistance sits at $200, then $220. A clean post-earnings close above $200 would matter because it would signal investors are willing to pay for software-AI optionality again.

Risk factors. The bear case is real. Enterprise software budgets remain under scrutiny, AI monetization is still uneven across the sector, and investors have grown unwilling to reward product demos without revenue conversion. If Q1 billings disappoint, guidance slips, or AI commentary sounds more like marketing than financials, the stock can retest its low.

Verdict: BUY, event-risk sized. My 12-month target band: $225–$245 base case, $262 stretch if the May 27 print stabilizes growth and shows credible AI attach-rate traction. Stop discipline below $160.

#3. Merck (MRK): BUY, healthcare ex-LLY with ASCO catalyst

Price: $122.41 | Market Cap: approximately $302.3B | Forward P/E: approximately 24x | 52W Range: $75.40 to $125.14 | Next catalyst: ASCO investor event on June 1, 2026

Thesis. Merck is the healthcare rotation pick because its catalyst is nearer than Lilly’s and its setup is less crowded than the GLP-1 trade. The stock carries a fresh oncology catalyst, a near-term ASCO event, and a pipeline story that can attract quality rotation from investors who want healthcare exposure without chasing LLY after several consecutive editions.

Why now. Merck announced that sacituzumab tirumotecan (sac-TMT) met its primary endpoints — overall survival and progression-free survival — in a Phase 3 trial for certain patients with advanced or recurrent endometrial cancer, outperforming chemotherapy on both measures. The ASCO investor event on June 1 gives the market a near-term, scheduled forum to reprice the broader oncology pipeline. That is a defined, unfired catalyst inside the window.

Key levels. Support sits near $116, then $110. Resistance sits near $125, the 52-week-high zone. A close through $125 would matter because it would show the stock is repricing the oncology platform — not just reacting to a single headline.

Risk factors. The upside here is measured, not explosive. Merck has already rallied and now sits close to its 52-week high. The longer-term debate — pipeline replacement, patent exposure, and Keytruda revenue concentration ahead of its 2028 US patent loss — still matters. This is a quality rotation setup, not a high-beta momentum trade.

Verdict: BUY for quality rotation — not a momentum chase. My 12-month target band: $132–$140 base case, $150 stretch if ASCO strengthens the oncology pipeline narrative. Stop discipline below $110.

6. Low-Cap Opportunities

Three setups, three verdicts, three catalysts.

The low-cap section is where the discipline has to be even stricter. These are not core compounders. They are asymmetric setups with smaller market caps, higher volatility, and narrower liquidity. The standard remains unchanged: under $15 billion market cap, explicit verdict, defined reference price, stop, and target band.

Oklo (OKLO): HOLD, nuclear momentum intact but entry is less clean

Reference Price: $65.88 | Market Cap: ~$11.2–11.5B | 52W Range: $44.88–$193.84 | Verdict: HOLD | Stop: $58 | Target Band: $83–$95 base, $120 stretch

Edition #18 held OKLO, and that posture still fits. The stock bounced from last week’s $62.25 reference to $65.88 — but the move did not create a cleaner entry, it removed one. The long-term nuclear and AI-power narrative remains intact; the problem is price and timing. Above $65, the stock needs either more execution proof or a better pullback to justify fresh capital.

OKLO remains one of the most direct public-market expressions of the nuclear-power, AI-data-center, and energy-security theme — which keeps it firmly relevant. But low-cap discipline means separating a good story from a good entry. The asymmetry is simply more attractive closer to the $58–$60 zone than it is here.

The stock is still pre-revenue and highly sensitive to policy headlines, capital-markets conditions, dilution risk, and sentiment toward long-duration energy-development stories. Rising yields can pressure it even while the nuclear thesis stays popular.

Verdict: HOLD. Do not chase. Revisit as a SPECULATIVE BUY only on a pullback toward $58–$60, or if a specific regulatory, commercial, or hyperscaler-linked catalyst improves the probability-weighted timeline.

Matador Resources (MTDR): HOLD, energy thesis intact but crude weakened the setup

Reference Price: $56.64 | Market Cap: ~$7.0B | 52W Range: $37.14–$66.84 | Verdict: HOLD | Stop: $54 | Target Band: $67–$74 base, $85 stretch

Edition #18 rated MTDR a SPECULATIVE BUY because geopolitical oil risk and the Brent rebound created a clean small-cap E&P setup. This week, the math changed. The stock closed at $56.64 — still above the $54 stop, but below the cleaner $58–$62 accumulation zone. The thesis is not broken; the crude tailwind is simply less forceful than it was a week ago.

Matador remains a direct Permian exposure under the $15 billion ceiling. If oil stabilizes or geopolitical risk reprices higher again, it can work quickly. But after crude eased from panic levels on peace-talk headlines, this is no longer a fresh aggressive buy — it is a hold-and-watch. The dominant risk is crude itself: if the geopolitical premium keeps unwinding, smaller E&P names can weaken even with solid company fundamentals. MTDR also stays sensitive to rates, sector flows, and investor appetite for cyclicals.

Verdict: HOLD. Keep the stop at $54. Upgrade back to SPECULATIVE BUY only if the stock reclaims $60 alongside crude stabilization, or if energy leadership returns.

AeroVironment (AVAV): HOLD, the #18 entry worked but chasing is lower quality

Reference Price: $174.23 | Market Cap: ~$8.7B | 52W Range: $156.00–$417.86 | Verdict: HOLD | Stop: $158 | Target Band: $200–$235 base, $300 stretch

Edition #18 upgraded AVAV back to SPECULATIVE BUY at the 52-week-low setup. That call worked — the stock closed at $174.23 after a strong Friday rebound. The defense-drone thesis remains intact, but the easy entry has passed. This is exactly where the publication’s discipline matters: a good call does not automatically become a good chase.

AVAV is still one of the cleaner public-market exposures to unmanned systems, tactical drones, and defense modernization, and it remains well below its 52-week high. The next earnings update can reset expectations if backlog, margins, and guidance cooperate. The setup is still active — just less attractive after the bounce. AVAV is volatile, earnings-sensitive, and narrative-heavy; the stock can move sharply if guidance disappoints or if investors decide the post-earnings reset needs more proof before a re-rating.

Verdict: HOLD. Do not chase above $175. Re-enter as a SPECULATIVE BUY on a pullback toward $160–$165, or on a confirmed breakout through $185 on volume.

7. Strategic Recap & Forward Outlook

By Friday, May 29, the market will likely have to answer three questions.

• Whether Nvidia’s print can carry the broader AI chain. If Broadcom, networking, AI-server, and data-center infrastructure names hold their bid, the AI trade has genuinely broadened. If they fail, Nvidia becomes a single-stock confirmation event rather than a market-wide acceleration signal.
• Whether software can stabilize. Salesforce reports May 27. Software has lagged while hardware captured the AI premium; a clean print — stable margins, no guide-down, credible monetization commentary — would let beaten-down software back into the conversation.
• Whether macro relief finally arrives. The May 28 inflation and spending data cluster matters because CPI and PPI already ran hot. A soft PCE print would help broaden the rally; a hot one pushes the market straight back into Fed-risk mode.

What would change the thesis

The bullish thesis breaks if the S&P 500 loses the 7,400 area while yields rise and software earnings miss — that combination would imply the week’s breadth was temporary, not durable. The AI thesis breaks if post-Nvidia suppliers fail to rally into their own catalysts; Nvidia alone is no longer enough. The low-cap thesis breaks if the Russell 2000 surrenders its outperformance — low-cap setups need breadth, liquidity, and risk appetite, and without them “cheap” can stay cheap.

Forward Outlook — Week of May 25–29, 2026

• Monday, May 25: US equity markets closed for Memorial Day. The holiday compresses the week and concentrates the weight onto Wednesday and Thursday.
• Tuesday, May 26: Light macro day. Watch positioning into Salesforce earnings, the PCE data, and the AI-infrastructure follow-through after Nvidia.
• Wednesday, May 27: Salesforce reports Q1 FY27 after the close — the software test of the week. A clean print can reopen the beaten-down software trade; a weak one reinforces the market’s preference for hardware and infrastructure over software-AI narratives.
• Thursday, May 28: Heavy macro calendar — April durable goods orders and new home sales, with PCE and personal income/outlays in focus. Costco reports Q3 after the close; Dell adds to the week’s AI-server demand read-through.
• Friday, May 29: Advance economic indicators, trade, inventories, and Chicago PMI. The Friday close will show whether the market absorbed Nvidia, Salesforce, PCE, and the holiday-shortened liquidity window cleanly.

Disclaimer

This analysis is for informational purposes only and should not be construed as investment advice. Equity markets carry substantial risk, including the potential loss of principal. Past performance does not guarantee future results. Price targets are based on analytical frameworks and current market data but involve significant uncertainty. Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.